Granted Patent B2

US 12,590,146 · App. 17/764,338 · Granted Mar 31, 2026

Inventors: Ming-Jin Jheng (Suzhou, CN); Wei Zhang (Suzhou, CN); Jieli Wang (Suzhou, CN)

Assignee: NONA BIOSCIENCES (SUZHOU) CO., LTD.

C07K16/28A61K47/68031A61K47/6849A61P35/00C12N5/10

Abstract

Claims (51)

1 . An antibody targeting CLDN18.2 or an antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, the light chain variable region comprises LCDR1, LCDR2 and LCDR3; wherein,

amino acid sequence of the HCDR1 is SEQ ID NO: 7, amino acid sequence of the HCDR2 is SEQ ID NO: 17, amino acid sequence of the HCDR3 is SEQ ID NO: 27, and amino acid sequence of the LCDR1 is SEQ ID NO: 41, amino acid sequence of the LCDR2 is SEQ ID NO: 48, and amino acid sequence of the LCDR3 is SEQ ID NO: 56; or,

amino acid sequence of the HCDR1 is SEQ ID NO: 8, amino acid sequence of the HCDR2 is SEQ ID NO: 18, amino acid sequence of the HCDR3 is SEQ ID NO: 28, and amino acid sequence of the LCDR1 is SEQ ID NO: 42, amino acid sequence of the LCDR2 is SEQ ID NO: 47, and amino acid sequence of the LCDR3 is SEQ ID NO: 57; or,

amino acid sequence of the HCDR1 is SEQ ID NO: 8, amino acid sequence of the HCDR2 is SEQ ID NO: 16, amino acid sequence of the HCDR3 is SEQ ID NO: 29, and amino acid sequence of the LCDR1 is SEQ ID NO: 42, amino acid sequence of the LCDR2 is SEQ ID NO: 47, and amino acid sequence of the LCDR3 is SEQ ID NO: 55; or,

amino acid sequence of the HCDR1 is SEQ ID NO: 8, amino acid sequence of the HCDR2 is SEQ ID NO: 16, amino acid sequence of the HCDR3 is SEQ ID NO: 29, and amino acid sequence of the LCDR1 is SEQ ID NO: 42, amino acid sequence of the LCDR2 is SEQ ID NO: 47, and amino acid sequence of the LCDR3 is SEQ ID NO: 58; or,

amino acid sequence of the HCDR1 is SEQ ID NO: 8, amino acid sequence of the HCDR2 is SEQ ID NO: 19, amino acid sequence of the HCDR3 is SEQ ID NO: 28, amino acid sequence of the LCDR1 is SEQ ID NO: 42, amino acid sequence of the LCDR2 is SEQ ID NO: 47, and amino acid sequence of the LCDR3 is SEQ ID NO: 57.

2 . The antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 , wherein,

the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 64 or a variant thereof, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 71 or a variant thereof;

or, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 67 or a variant thereof, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 73 or a variant thereof;

or, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72 or a variant thereof;

or, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 68 or a variant thereof, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 74 or a variant thereof;

or, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 66 or a variant thereof, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72 or a variant thereof;

wherein, the variant retains at least function of pre-mutated sequence, and the variant has at least 85% identity to the pre-mutated sequence.

3 . The antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 , wherein, the antibody targeting CLDN18.2 further comprises an antibody heavy chain constant region and an antibody light chain constant region.

4 . The antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 3 , which is a full-length antibody comprising a heavy chain and a light chain; wherein,

the heavy chain comprises the amino acid sequence of SEQ ID NO: 77, and the light chain comprises the amino acid sequence of SEQ ID NO: 93;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 78, and the light chain comprises the amino acid sequence of SEQ ID NO: 94;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 79, and the light chain comprises the amino acid sequence of SEQ ID NO: 93;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 85, and the light chain comprises the amino acid sequence of SEQ ID NO: 93;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 83, and the light chain comprises the amino acid sequence of SEQ ID NO: 93;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 84, and the light chain comprises the amino acid sequence of SEQ ID NO: 93;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 81, and the light chain comprises the amino acid sequence of SEQ ID NO: 95;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 82, and the light chain comprises the amino acid sequence of SEQ ID NO: 96;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 80, and the light chain comprises the amino acid sequence of SEQ ID NO: 94;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 86, and the light chain comprises the amino acid sequence of SEQ ID NO: 95;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 87, and the light chain comprises the amino acid sequence of SEQ ID NO: 96;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 88, and the light chain comprises the amino acid sequence of SEQ ID NO: 94;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 89, and the light chain comprises the amino acid sequence of SEQ ID NO: 95;

or, the heavy chain comprises the amino acid sequence of SEQ ID NO: 90, and the light chain comprises the amino acid sequence of SEQ ID NO: 96.

5 . A biomaterial encoding the antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 , wherein, the biomaterial is selected from the group consisting of:

(i) an isolated nucleic acid;

(ii) a recombinant expression vector comprising the isolated nucleic acid of (i);

(iii) a transformant, which is a host cell comprising the recombinant expression vector of (ii).

6 . A medicament comprising the antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 , wherein, the medicament is selected from the group consisting of: (i) a chimeric antigen receptor; (ii) a genetically modified cell; (iii) an antibody drug conjugate; wherein the antibody drug conjugate further comprises a cytotoxic agent; (iv) a pharmaceutical composition, wherein, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

7 . A kit comprising the antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 .

8 . A method for diagnosing or treating a CLDN18.2-mediated disease or symptom, which comprises: administering to a subject in need of a therapeutically effective amount of the antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 ; the disease or symptom is a tumor.

9 . A method of immunoassaying or measuring CLDN18.2, which comprises the antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 .

10 . A combination therapy, which comprises: administering the antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 1 and a second therapeutic agent, respectively, to a subject in need; the second therapeutic agent comprises other anti-tumor antibodies or a pharmaceutical composition containing the other anti-tumor antibodies, or one or more of the group consisting of hormone agents, targeted small molecule agents, proteasome inhibitors, imaging agents, diagnostic agents, chemotherapeutic agents, oncolytic drugs, cytotoxic agents, cytokines, activators of co-stimulatory molecules, inhibitors of inhibitory molecules and vaccines.

11 . The antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 7 , wherein the heavy chain constant region is selected from hIgG1, hIgG2, hIgG3 or hIgG4 or variants thereof, and the light chain constant region is selected from κ chain or λ chain of a human antibody or variants thereof.

12 . The antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 11 , wherein the heavy chain constant region is hIgG1, and the light chain constant region is κ chain of a human antibody.

13 . The antibody targeting CLDN18.2 or the antigen-binding fragment thereof of claim 3 , wherein the antibody targeting CLDN18.2 is a full-length antibody, a Fab, a Fab′, a F(ab′) 2 , a Fv, a scFv, a bispecific antibody, a multispecific antibody, or a monoclonal antibody or a polyclonal antibody derived from the antibody as defined above.

14 . The biomaterial according to claim 5 , wherein the recombinant expression vector is a plasmid, a cosmid, a phage or a viral vector;

or, the host cell is an E. coli TG1, a BL21 cell or a CHO-K1 cell.

15 . The medicament of claim 6 ,

wherein the genetically modified cell is a eukaryotic cell;

wherein the cytotoxic agent is MMAF or MMAE;

wherein the pharmaceutical composition further comprises one or more of the group consisting of hormone agents, targeted small molecule agents, proteasome inhibitors, imaging agents, diagnostic agents, chemotherapeutic agents, oncolytic drugs, cytotoxic agents, cytokines, activators of co-stimulatory molecules, inhibitors of inhibitory molecules and vaccines.

16 . The medicament of claim 15 , wherein the genetically modified cell is an isolated human immune cell.

17 . The kit according to claim 7 , wherein the kit further comprises (i) a device for administering an antibody or an antigen binding fragment thereof, or an antibody drug conjugate or a pharmaceutical composition; or (ii) instructions for use.

18 . The method according to claim 8 , wherein the tumor is a CLDN18.2 positive tumor.

19 . The method according to claim 18 , wherein the CLDN18.2 positive tumor is gastric cancer, esophageal cancer, lung cancer, ovarian cancer, melanoma, renal cancer, breast cancer, colorectal cancer, liver cancer, pancreatic cancer, bladder cancer, head and neck cancer, bronchial cancer, glioma or leukemia.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (50)